IL2 and melanoma: Lastly, BREAK-3 was a large multicenter open-label randomized phase III clinical trial that enrolledpatients with previously untreated (other than with interleukin-2) BRAF V600E-mutated stage IV melanoma(Hauschild et al., 2012).